36. The composition of claim 35 which composition comprises EC145 at a concentration of 1.4 mg/mL in an aqueous sterile liquid formulation the components of which comprise pH 6.2 citrate buffer, mannitol and water for injection.

37. Use of a solid pharmaceutical composition according to claim 1 or 20 in the manufacture of a medicament for ~~A method of~~ treating a patient with a tumor bearing functionally active folate receptors ~~comprising at least one of the steps of:~~

~~(a) dissolving~~wherein the solid pharmaceutical composition ~~described in claim 1 or 20~~is to be dissolved in a pharmaceutically acceptable solvent to produce a pharmaceutically acceptable solution, and wherein

~~(b) administering~~ the solution is to be administered to the patient in need thereof.

38. The ~~method~~ use of claim 37, wherein the tumor is an ovarian tumor or a lung tumor.

39. The ~~method~~ use of claim 38 wherein the tumor is an ovarian tumor.

40. The ~~method~~ use of claim 39 wherein the tumor is a platinum-resistant ovarian tumor.

41. The ~~method~~ use of claim 37 wherein the patient is to be further treated with pegylated liposomal doxorubicin or with doxorubicin which is not of the pegylated liposomal form.